Scarica l'app Stockscreener
14.70
4.55%
-0.70
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AVTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.40
Aprire:
$15.66
Volume 24 ore:
6.42M
Relative Volume:
3.91
Capitalizzazione di mercato:
$772.71M
Reddito:
$59,000
Utile/perdita netta:
$-84.74M
Rapporto P/E:
-2.5248
EPS:
-5.8222
Flusso di cassa netto:
$-59.69M
1 W Prestazione:
+7.53%
1M Prestazione:
-9.03%
6M Prestazione:
-22.26%
1 anno Prestazione:
+208.82%
Intervallo 1D:
$14.59
$15.93
Intervallo di 1 settimana:
$13.96
$15.93
Portata 52W:
$4.50
$24.27
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Nome
Avalo Therapeutics Inc
Settore
Industria
Telefono
410-522-8707
Indirizzo
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVTX
Avalo Therapeutics Inc
|
14.70 | 772.71M | 59,000 | -84.74M | -59.69M | -5.8222 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-04-06 | Iniziato | Citizens | Mkt Outperform |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-09-17 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-05 | Iniziato | TD Cowen | Buy |
| 2025-08-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-03-25 | Iniziato | Jefferies | Buy |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-28 | Iniziato | Piper Sandler | Overweight |
| 2025-02-21 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-10-24 | Iniziato | H.C. Wainwright | Neutral |
| 2024-04-16 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-24 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie
Avalo Therapeutics Inc (AVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Avalo Therapeutics Inc (AVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Avalo Therapeutics Inc (AVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avalo Therapeutics Inc (AVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Avalo Therapeutics Inc (AVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Avalo Therapeutics Inc (AVTX) Institutional Confidence - TradingKey
Avalo Therapeutics Inc (AVTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Avalo Therapeutics Inc (AVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Avalo Therapeutics advances AVTX-010 - TipRanks
Avalo Therapeutics amends preferred stock terms and executive agreements By Investing.com - Investing.com Nigeria
Avalo Therapeutics (AVTX) Advances Next-Gen Anti-IL-1beta Antibo - GuruFocus
Avalo Therapeutics advances AVTX-010 for hidradenitis suppurativa - BioWorld News
Avalo Therapeutics Expands Pipeline With New IL-1β Antibody - TipRanks
Avalo Therapeutics Expands Pipeline with AVTX-010, A Long-Acting Next-Generation Anti-Il-1? Antibody - marketscreener.com
Avalo Therapeutics plans IND submission for AVTX-010 in H1 2027 - Investing.com
Avalo Therapeutics advances long‑acting IL‑1β candidate AVTX-010, IND planned for 1H 2027 - TradingView
Avalo develops longer-lasting antibody to enable less frequent dosing - Stock Titan
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody - GlobeNewswire
Avalo Therapeutics stock soars after positive LOTUS trial results - MSN
AVTX News | AVALO THERAPEUTICS INC (NASDAQ:AVTX) - ChartMill
Avalo Therapeutics Expands Ownership Limits, Updates Executive Contracts - The Globe and Mail
AVTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
Avalo Therapeutics amends preferred stock terms and executive agreements - Investing.com
Avalo Therapeutics (AVTX) CSO logs 588-share tax-withholding transaction - Stock Titan
Avalo Therapeutics (AVTX) CLO logs tax-withholding of 1,081 shares on Form 4 - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) CFO logs tax-withholding share move - Stock Titan
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Avalo Therapeutics (NASDAQ: AVTX) creates Series C-1 preferred and enhances executive change-in-control pay - Stock Titan
BofA Securities Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $35 - Moomoo
This Keurig Dr Pepper Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
BofA initiates Avalo Therapeutics stock with buy rating on HS drug - Investing.com Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
FMR LLC's Strategic Acquisition of Avalo Therapeutics Inc Shares - GuruFocus
Avalo Therapeutics: Sell-Off Could Continue If Overall Market Deteriorates Further - Seeking Alpha
Avalo Therapeutics Shareholders Back Directors and Governance Changes - The Globe and Mail
Avalo Therapeutics elects directors, approves stock plan and auditor at annual meeting - Investing.com UK
Avalo Therapeutics (AVTX) holders approve ESPP, elect 7 directors and ratify Ernst & Young - Stock Titan
Avalo Therapeutics prices $375 million stock offering By Investing.com - Investing.com Nigeria
FMR LLC amendment shows 3.19M shares in Avalo Therapeutics (AVTX) - Stock Titan
Deep Track Capital, LP Acquires Significant Stake in Avalo Thera - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in Avalo Therapeutics Inc - GuruFocus
Director at Avalo Therapeutics (AVTX) granted 20,100 stock options - Stock Titan
Avalo Therapeutics (AVTX) director receives grant of 20,100 stock options at $13.96 - Stock Titan
Avalo Therapeutics (AVTX) director receives 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director receives stock options for 20,100 shares - Stock Titan
Avalo Therapeutics (AVTX) director awarded 29,500 options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) director granted 20,100 stock options at $13.96 strike - Stock Titan
Avalo Therapeutics (AVTX) Edges Higher as Stock Tests Key Near-Term ResistanceBPI Bear Correction - newsline.com
AVTX: Broker-listed notice for proposed sales of 43,?33 shares (06/02/2026) - Stock Titan
Avalo Therapeutics (AVTX) CMO sells shares under 10b5-1 plan - Stock Titan
Avalo Therapeutics Inc Azioni (AVTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):